Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2022 | CB011: a novel genome-engineered BCMA-specific CAR-T cell therapy

In this video, Steven Kanner, PhD, Caribou Biosciences, Berkeley, CA, explains a novel BCMA-specific allogeneic chimeric antigen receptor T-cell (CAR-T) therapy known as CB-011, and the genome-editing technology behind this product. First, Dr Kanner discusses how CRISPR hybrid RNA-DNA (chRDNA), a highly specific form of genome editing, is implemented into allogeneic CAR-T and natural killer (NK) therapies to increase the persistence of these cells. Dr Kanner then provides more detail on the strategy behind CB-011, explaining how the knocking out of class I antigens on the CAR-T cells and insertion of a fusion protein prevents cytotoxic T-cells from reacting against CB-011, and NK cells from rejecting the graft. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.